Gelteq Ltd (GELS) shareholders
GELSNasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Jun 30, 2025Last filing: 20-F on Nov 16, 2026Score 0/30
$0.27−0.09 (-25.05%)
Close on Nov 17, 2026Market cap $2.88MP/E –Yield –
Ownership
Who owns Gelteq's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Paul Michael WYNNE | Chief Scientific Officer | – | – | Mar 18, 2026 |
| Bradley Glenn Karp | Head of Sales and Marketing | 500,000 | 4.67% | Mar 18, 2026 |
| Nathan J. Givoni | Chief Executive Officer | 657,087 | 6.13% | Mar 18, 2026 |
| Simon H. Szewach | Director | 338,197 | 3.16% | Mar 18, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
2.1
At 0M shares a day
Change since last report
-27.5%
From 0M shares
Short volume, 20 days
32.3%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Gelteq's stock actually held short. Settlement fails (shares not delivered on time) peaked at 481,563 shares on Sep 4, 2026 over the last 90 days.
See a number that looks wrong?